Ann: Xanamen Clinical Development & Investor Update, page-5

I think more so they want to have the ability from the FDA to use larger doses over longer periods of time. I think the advisory board and BODs understand that higher dosages are better already.

patient type is an interesting point. From what I can gather it suggests that some were effected more than others. It will be interesting to see why and how much by. Perhaps lower tolerance?

Something interesting to consider. The targeted mild AD population was approx 2 million. The depression targeted population is close to 14 million. Logically the company would target this instead of AD. Not just for population but investor confidence. Ideally we go hard at all 4 potential indications but I don't see this being likely.